🔗 Share this article

As the US undertakes sweeping adjustments to its immunization schedules, a particular individual has emerged in a surprising turn: Dr. Tracy Beth Høeg, a Danish American physician and epidemiologist who first made her name by questioning coronavirus vaccinations in the pandemic and has focused upon possible fatalities after COVID-19 immunization in her short tenure at the Food and Drug Administration.

Scheduled Overhauls to Childhood Immunization Schedule

Public health authorities planned to reveal sweeping changes to the pediatric vaccine schedule earlier this month, bringing the US with Denmark’s immunization schedule, sources say – a major change that would place the US out of step with much of the international standard with no evidence for public health gain. The announcement has been delayed until the next year.

Rather than Vinay Prasad, Dr. Høeg is scheduled to address the audience at the gathering. She was newly appointed temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to run the center this calendar year.

Consolidating Power at the Agency

The acting appointment may indicate a closer partnership between the pharmaceutical and vaccine divisions as Høeg and Prasad consolidate power at the regulatory agency – and it signals a increased emphasis upon dismantling already-approved immunizations at the FDA.

Høeg has often pushed for ending certain childhood shot schedules in the US so as to align more in line with the Danish model, a country with comprehensive healthcare and a population approximately the population of Wisconsin’s.

To date comments, she has persisted in emphasizing on vaccines – usually the domain of Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than medication approval.

Concerns Over Expertise

Høeg has no obvious background in pharmaceutical research, approval processes or management, which has been customary for former heads of the biologics center. She has worked at the FDA as a key advisor to the agency head and CBER since spring.

“She appears not to have the necessary background” for leading the CDER, stated Jonathan Howard. “She lacks experience running a randomized controlled trial. She lacks experience in running a large organization. She has no expertise in pharmaceutical oversight.”

Previous commissioners of CBER would “be deeply familiar with legal statutes and the research of drug development”, commented a former acting FDA commissioner. “Frankly, she has not acquired the sort of resume that prior appointees who led CBER have had.”

The drug center has an immense workload at the FDA, Woodcock emphasized.

“Everybody just focuses on the innovative therapies, but the off-patent medication office approves numerous off-brand pharmaceuticals. There is also a biologic copycat branch, over-the-counter program and so forth, and all of those need to be managed,” Woodcock explained. “The responsibility you overlook, that is precisely what that I always told people is going to cause problems.”

Furthermore, a substantial leadership element to the job, which manages in excess of 5,000 staff members. “It is a enormous management job, if you do it right,” the former official said.

Response and Controversial Initiatives

When asked about concerns about Dr. Høeg's qualifications and whether this appointment indicates greater collaboration among agency officials on vaccines, a press secretary said that the “questions are based on incorrect assumptions”.

“Her experience aligns with the functions of her role,” the official explained, noting the time Dr. Høeg spent advising the agency head on “pharmaceutical safety and regulatory science, including computational safety modeling and vaccine surveillance”.

As acting director, Høeg inherits the agency head's recently launched fast-track approval initiative, a controversial rapid therapy clearance system that reportedly troubled her preceding directors. “By what process are these medications being selected for this voucher program? Who takes the decisions?” Dr. Howard asked. “There’s a lot of secrecy occurring at the agency right now.”

Overall, he said, “the Food and Drug Administration looks to be trending towards laxer regulations of most medications, with the exception of immunizations.”

Established Track Record on Immunizations

Concerning immunizations, Dr. Høeg has a more established, if troubling, past, some experts have noted. She authored a study using unconfirmed volunteer-provided data to estimate the incidence of myocarditis following Covid vaccination. She consulted for the Florida top health official Joseph Ladapo, who allegedly have modified findings to suggest COVID-19 vaccines are riskier than they are.

Among her “wish list” for the incoming federal leadership encompassed changing guidelines for novel immunizations and discontinuing “optional” immunizations, she said after the election on a online show. At the agency, Høeg has reportedly floated the idea of preventing young men from obtaining Covid vaccinations.

“She’s an complete dogmatist who commences with her preconceived notions and reverse-engineers to fit the science in a extremely misleading, fraudulent fashion,” Dr. Howard argued.

Taking Control and a “Push for Payback”

Høeg aligned with other skeptics, {like|